BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Barts Hospital, London Enrolls First Patients in Rox Medical Inc.'s CONTROL-HTN Resistant Hypertension Trial


3/25/2013 9:40:30 AM

SAN CLEMENTE, Calif., March 25, 2013 /PRNewswire/ -- St Bartholomew's and the London NHS Trust (Barts) have enrolled their first patients in the ROX Medical CONTROL-HTN international randomized controlled hypertension trial. The CONTROL-HTN trial is evaluating the ROX FLOW procedure - creating a small connection between artery and vein in the upper leg - for the treatment of resistant hypertension. Dr. Mel Lobo and Prof. Mark Caulfield enrolled the first patients at Barts Hospital. The first two patients randomized to the treatment group received the ROX procedure successfully performed by Dr. Ajay Kumar Jain and Prof. Anthony Mathur from the Cardiology department.

"We are very excited to be part of this trial which could lead to a novel new therapy option for resistant hypertension," commented Dr. Lobo. "We are impressed with the ease of the procedure, the need for minimal anesthesia and like the fact that it is reversible."

ROX Medical's FLOW procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance by diverting some of the higher-pressure arterial blood to the low pressure and highly compliant venous system; essentially restoring some of the lost compliance back into the vascular system. Because the FLOW procedure does not target the sympathetic nerves or arteries of the kidneys, it may be of benefit to those patients who either cannot have or have failed to respond to renal denervation. "Because the ROX FLOW procedure is reversible and leaves all other therapy options open, we are finding more patients and physicians who see this as a first choice device therapy option for resistant hypertension," commented ROX CEO Rodney Brenneman.

"Resistant hypertension patients are a challenge for hypertension specialists and there is a need for new therapy options," added Dr. Lobo. "We are looking forward to enrolling our next patients and watching their progress over the coming months."

The ROX FLOW procedure for hypertension is not approved for use in the U.S.

SOURCE ROX Medical



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES